DVA Stock Surges 41% With A 7-day Winning Spree On Record Earnings Beat
DaVita (DVA) – a provider of kidney dialysis and related laboratory services – hit a 7-day winning streak, with cumulative gains over this period amounting to 41%. The company’s market cap has surged by about $3.1 Bil over the last 7 days and currently stands at $11 Bil.
The stock has YTD (year-to-date) return of 31.3% compared to -0.7% for S&P 500. This calls for a re-evaluation of the stock’s valuation to find out whether this is an opportunity or a trap.
What Triggered The Rally?
[1] Stellar Q4 Earnings & 2026 Guidance
- Why Chevron Stock May Drop Soon
- Ralph Lauren Stock: A Compounding Engine Facing Its North American Test
- How Broadcom Ends Nvidia’s GPU Monopoly
- Is Royal Caribbean Stock A Trap Or A Missed Opportunity?
- Beyond Price Action: Does DG Offer Genuine Diversification?
- Kyndryl Stock: Strong Cash Flow Poised for a Re-Rating?
- Q4 Adj EPS $3.40 vs $3.24 est
- FY26 EPS guide $13.60-$15.00 vs $12.89 est
- Impact: Stock gapped up over 24%, Heavy institutional buying volume
Opportunity or Trap?
Below is our take on valuation.
There are a few things to fear in DVA stock given its overall Weak operating performance and financial condition. Hence, despite its Low valuation, this makes the stock look Risky (For details, see Buy or Sell DVA).
But here is the real interesting point.
You are reading about this 41% move after it happened. The market has already priced in the news. To catch the next winner before the headlines, you need predictive signals, not notifications. Our High Quality Portfolio has flagged 5 new opportunities that have not surged yet.
Returns vs S&P 500
The following table summarizes the return for DVA stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | DVA | S&P 500 |
|---|---|---|
| 1D | 5.0% | -1.2% |
| 7D (Current Streak) | 41.3% | -2.6% |
| 1M (21D) | 30.1% | -2.1% |
| 3M (63D) | 24.4% | 0.4% |
| YTD 2026 | 31.3% | -0.7% |
| 2025 | -24.0% | 16.4% |
| 2024 | 42.8% | 23.3% |
| 2023 | 40.3% | 24.2% |
However, big gains can follow sharp reversals – but how has DVA behaved after prior drops? See DVA Dip Buyer Analysis to learn more.
Gains and Losses Streaks: S&P 500 Constituents
There are currently 85 S&P constituents with 3 days or more of consecutive gains and 50 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 36 | 25 |
| 4D | 16 | 7 |
| 5D | 8 | 4 |
| 6D | 13 | 3 |
| 7D or more | 12 | 11 |
| Total >=3 D | 85 | 50 |
Key Financials for DaVita (DVA)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $12.1 Bil | $12.8 Bil |
| Operating Income | $1.6 Bil | $2.0 Bil |
| Net Income | $691.5 Mil | $936.3 Mil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ2 | 2025 FQ3 |
|---|---|---|
| Revenues | $3.4 Bil | $3.4 Bil |
| Operating Income | $530.5 Mil | $495.6 Mil |
| Net Income | $199.3 Mil | $150.3 Mil |
While DVA stock looks attractive given its winning streak, investing in a single stock without detailed, thorough analysis can be risky. The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.